Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sunil Sharma

Showing results (361-370 of 429) with videos related to

Pageof 43
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group studyTimothy W Synold, Chris H Takimoto, James H Doroshow, et al.
Molecular Cancer Therapeutics|January 18, 2014
Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cellsWarren Fiskus, Sunil Sharma, Jun Qi, et al.
The Oncologist|August 20, 2020
Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I StudyJohanna Bendell, Sunil Sharma, Manish R Patel, et al.
Cancer Research and Treatment|January 25, 2024
Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid TumorsYoon-Koo Kang, Min-Hee Ryu, Yong Sang Hong, et al.
The Lancet. Haematology|January 8, 2024
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 studyPau Abrisqueta, Eva González-Barca, Carlos Panizo, et al.
Frontiers in Immunology|August 18, 2025
NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancerJoanna Palade, Eric Alsop, Nanyun Tang, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 24, 2020
Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapyJason I Griffiths, Pierre Wallet, Lance T Pflieger, et al.
Annals of Surgical Oncology|December 5, 2002
Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV diseaseGarrett M Nash, Leonard B Saltz, Nancy E Kemeny, et al.
Plos One|July 11, 2020
The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancerRaffaella Soldi, Tithi Ghosh Halder, Alexis Weston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2018
Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I StudyManish A Shah, Alexander Starodub, Sunil Sharma, et al.
Pageof 43

Showing results (361-370 of 429) with videos related to

Sort By:
Pageof 43
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group studyTimothy W Synold, Chris H Takimoto, James H Doroshow, et al.
Molecular Cancer Therapeutics|January 18, 2014
Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cellsWarren Fiskus, Sunil Sharma, Jun Qi, et al.
The Oncologist|August 20, 2020
Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I StudyJohanna Bendell, Sunil Sharma, Manish R Patel, et al.
Cancer Research and Treatment|January 25, 2024
Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid TumorsYoon-Koo Kang, Min-Hee Ryu, Yong Sang Hong, et al.
The Lancet. Haematology|January 8, 2024
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 studyPau Abrisqueta, Eva González-Barca, Carlos Panizo, et al.
Frontiers in Immunology|August 18, 2025
NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancerJoanna Palade, Eric Alsop, Nanyun Tang, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 24, 2020
Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapyJason I Griffiths, Pierre Wallet, Lance T Pflieger, et al.
Annals of Surgical Oncology|December 5, 2002
Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV diseaseGarrett M Nash, Leonard B Saltz, Nancy E Kemeny, et al.
Plos One|July 11, 2020
The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancerRaffaella Soldi, Tithi Ghosh Halder, Alexis Weston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2018
Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I StudyManish A Shah, Alexander Starodub, Sunil Sharma, et al.
Pageof 43